Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681954 | 0.81 | MAPT (0.40) | FFAR4HRH3CYP2C9 | |
| SCHEMBL4773141 | 0.77 | FFAR1 (0.36) | FFAR1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL3526047 | 0.75 | FFAR1 (0.35) | FFAR1CYP4F2CYP4A11 | |
| SCHEMBL2680595 | 0.75 | FFAR4 (0.49) | FFAR1FFAR4PDE4DCYP2C9PDE4A | |
| SCHEMBL3803873 | 0.75 | FFAR4 (0.49) | FFAR1FFAR4PDE4DCYP2C9PDE4A | |
| SCHEMBL3803876 | 0.75 | FFAR4 (0.49) | FFAR1FFAR4PDE4DCYP2C9PDE4A | |
| SCHEMBL3096469 | 0.75 | FFAR1 (0.42) | FFAR1FFAR4CYP4F2CYP4A11 | |
| SCHEMBL7868639 | 0.73 | FFAR1 (0.68) | FFAR1FFAR4HDAC4 | |
| SCHEMBL6994406 | 0.73 | FFAR1 (0.68) | FFAR1FFAR4HDAC4 | |
| SCHEMBL2681413 | 0.71 | FFAR1 (0.47) | FFAR1FFAR4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | FFAR1 194/4885FFAR4 134/4885CYP4F2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.